Scholarlink

Background <p>Cisplatin resistance remains a major obstacle in the treatment of ovarian cancer (OC). Although <i>ELK3</i>, an ETS transcription factor, has been implicated in chemoresistance across various cancers, its specific role and molecular mechanisms in OC progression and cisplatin resistance remain poorly understood.</p> Methods <p><i>ELK3</i> expression was analyzed in cisplatin-resistant OC cells using qPCR and Western blotting. Functional assays, including CCK-8, apoptosis analysis, and xenograft models, were employed to assess the impact of <i>ELK3</i>. Mechanistic insights were gained through Co-IP and histone lactylation analysis.</p> Results <p><i>ELK3</i> was significantly upregulated in cisplatin-resistant OC tissues and cells, and its elevated expression correlated with poor patient survival according to TCGA and KM Plotter data. Knockdown of <i>ELK3</i> sensitized OC cells to cisplatin by suppressing CHD4 expression and reducing histone lactylation levels. Importantly, restoration of CHD4 expression rescued cisplatin resistance in <i>ELK3</i>-deficient cells.</p> Conclusion <p>The <i>ELK3</i>-<i>CHD4</i>-histone lactylation axis plays a critical role in driving cisplatin resistance in OC, highlighting its potential as a novel therapeutic target for overcoming chemoresistance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ELK3 promotes cisplatin resistance in ovarian cancer via regulating CHD4 gene expression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月19日

查看全文
  • Qihua Peng,
  • Kaho Leung,
  • Yixuan Sun,
  • Shiyu Zhang,
  • Yincheng Teng,
  • Xiaojuan Dong

摘要

Background

Cisplatin resistance remains a major obstacle in the treatment of ovarian cancer (OC). Although ELK3, an ETS transcription factor, has been implicated in chemoresistance across various cancers, its specific role and molecular mechanisms in OC progression and cisplatin resistance remain poorly understood.

Methods

ELK3 expression was analyzed in cisplatin-resistant OC cells using qPCR and Western blotting. Functional assays, including CCK-8, apoptosis analysis, and xenograft models, were employed to assess the impact of ELK3. Mechanistic insights were gained through Co-IP and histone lactylation analysis.

Results

ELK3 was significantly upregulated in cisplatin-resistant OC tissues and cells, and its elevated expression correlated with poor patient survival according to TCGA and KM Plotter data. Knockdown of ELK3 sensitized OC cells to cisplatin by suppressing CHD4 expression and reducing histone lactylation levels. Importantly, restoration of CHD4 expression rescued cisplatin resistance in ELK3-deficient cells.

Conclusion

The ELK3-CHD4-histone lactylation axis plays a critical role in driving cisplatin resistance in OC, highlighting its potential as a novel therapeutic target for overcoming chemoresistance.